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DLSThe aim of the present study was to encapsulate mannosylated 1-aminoadamantane and mannosylated
adamantyltripeptides, namely [(2R)-N-(adamant-1-yl)-3-(α,β-D-mannopyranosyloxy)-2-methylpropanamide
and (2R)-N-[3-(α-D-mannopyranosyloxy)-2-methylpropanoyl]-D,L-(adamant-2-yl)glycyl-L-alanyl-D-isoglutamine]
in liposomes. The characterization of liposomes, size and surface morphology was performed using dynamic light
scattering (DLS) and atomic forcemicroscopy (AFM). The results have revealed that the encapsulation of examined
compounds changes the size and surface of liposomes. After the concanavalin A (ConA) was added to the liposome
preparation, increase in liposome size and their aggregation has been observed. The enlargement of liposomes was
ascribed to the speciﬁc binding of the ConA to themannose present on the surface of the prepared liposomes. Thus, it
has been shown that the adamantyl moiety from mannosylated 1-aminoadamantane and mannosylated adaman-
tyltripeptides can be used as an anchor in the lipid bilayer for carbohydratemoiety exposed on the liposome surface.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The discovery of antiviral activity of amantadine (1-aminoadaman-
tane hydrochloride, Symmetrel®) in 1964 has stimulated the intensive
research of new adamantane derivatives and studies of the mechanism
of their action [1,2]. A series of adamantane derivatives has been widely
used in the treatment of various diseases, including inﬂuenza [1–4] and
Parkinson's disease [5,6]. The mechanism by which amantadine exerts
its antiviral activity is not yet clearly understood although some aspects
of its possible mechanism of action have been discussed [7–9]. More re-
cent studies have demonstrated that amantadine is a weak, non-
competitive N-methyl-D-aspartic acid (NMDA) receptor antagonist
[10,11].
It is well known that introducing an adamantyl moiety with its
unique physicochemical properties, into substances with known bi-
ological activity improves their pharmacological properties and en-
hances their activity [12]. The multidimensional value of the
adamantyl group in drug design has been stressed in several recent
review papers [13,14]. In our previous investigations we reported
the synthesis of adamant-2-yl-tripeptides [15]. The described ada-
mantyltripeptides belong to a class of immunomodulating com-
pounds comprising the elements of the bacterial peptidoglycanand Development, Institute of
Tel.: +385 1 6414 213; fax:
).
l rights reserved.structures. Thus, the dipeptide, L-Ala-D-isoGln, characteristic for
the bacterial cell wall peptidoglycans was bound to the adamantyl
moiety through the glycine molecule. Two diastereoisomers (D- and L-
(adamant-2-yl)Gly-L-Ala-D-isoGln) formed due to the different abso-
lute conﬁgurations of adamantylglycinewere characterized and biolog-
ically evaluated in several model systems [16–19]. In order to possibly
improve their biological activity the examined adamantyltripeptides
were incorporated into liposomes. Therefore a reliable quantitative
high performance liquid chromatography (HPLC) method was devel-
oped for the determination of the entrapment efﬁciency for the studied
compounds [20]. We were also interested in the possible interaction of
adamantyltripeptides with the lipid bilayer of liposomes. The investiga-
tionswere carried out using the electron paramagnetic resonance spec-
troscopy (EPR) and the results conﬁrmed that adamantyltripeptides
interact with the lipid in bilayers [21].
Liposomes have been recognized as an artiﬁcial model mem-
brane system and have been used for different biochemical and
biophysical studies of the cell. Among others, the important advan-
tage of using liposomes is that they can incorporate different
membrane-active agents into the lipid bilayer and thus create a
number of artiﬁcial membrane structures [22]. The studies of
model liposomal systems have provided a useful approach to un-
derstanding the complex processes in biological systems. Liposomal
nanoparticles are also pharmaceutically proven delivery vehicles
that can encapsulate a therapeutic agent and also display ligands
that target the cell-surface receptors [23]. Recent developments in
the carbohydrate-decorated targeted drug delivery have opened
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The main challenge has been to identify a ligand that provides sufﬁ-
cient selectivity for the targeted cells. Several reports have documen-
ted the potential of glycan ligands for targeting glycan-binding
proteins that exhibit restricted expression on immune cell subsets.
The mannosylated liposomes are recognized as attractive drug deliv-
ery carriers that are characterized by the absence of toxicity and a
low intrinsic immunogenicity [26–28]. Mannose receptors (MR) pre-
sent on the cell surface of different immunocompetent cells such as
macrophages and dendritic cells, are considered to be pattern-
recognition receptors binding compounds comprising mannose
(Man), N-acetylglucosamine (GlcNAc) and fucose. Therefore, they
could be responsible for the receptor mediated uptake of mannosy-
lated antigens, relevant biologically active molecules containing man-
nose or mannose targeted drug delivery systems, thus affecting the
immune reactions. We have recently reported the synthesis of man-
nose conjugates of 1-aminoadmantane and adamant-2-yl tripeptides
[29,30]. The aim of the present studywas to encapsulate themannosy-
lated 1-aminoadamantane and mannosylated adamantyltripeptides,
namely [(2R)-N-(adamant-1-yl)-3-(α,β-D-mannopyranosyloxy)-2-
methylpropanamide and (2R)-N-[3-(α-D-mannopyranosyloxy)-2-
methylpropanoyl]-D,L-(adamant-2-yl)glycyl-L-alanyl-D-isoglutamine]
(Fig. 1), into liposomes and characterize them by using high perfor-
mance liquid chromatography (HPLC), dynamic light scattering
(DLS) and atomic force microscopy (AFM) in order to obtain data
about encapsulation efﬁciency, size and properties of the liposomes
and lipid bilayer structure. The choice of compounds to be encapsulat-
ed was based on the results of immunotestings [30] which indicated
that the (R)-absolute conﬁguration of the chiral linker connecting
the sugar and adamantyltripeptide parts of the molecule, enhanced
the biological activities of the tested immunostimulators. We have
shown previously [30] that the ratio of particular diastereoisomers
in the diastereoisomeric mixture, determined by HPLC, was 3:2, re-
garding the L-L-D:D-L-D amino acid sequence in the tripeptide part
of the molecule.
The physical characteristics and morphology (i.e. size, shape,
lamellarity, charge, bilayer ﬂuidity and chemical stability) of lipo-
somes as drug delivery systems directly inﬂuence their efﬁciency
in vitro and in vivo and have to be assessed. In that sense various
analytical techniques have been applied. E.g. dynamic light scatter-
ing (DLS) is frequently used in determination of liposome size dis-
tribution and the electron paramagnetic resonance spectroscopy
(EPR) has been used to investigate the lamellarity and permeabil-
ity of the lipid bilayer and the inﬂuence of liposome size on the
substances pharmacokinetics [31,32]. Atomic force microscopy
(AFM) is a technique that uses a very sharp probe tip to image
the topography of surfaces at a lateral resolution better than
1 nm and a vertical resolution of 0.1 nm, under ambient condi-
tions. It is a ﬁrst-choice technique in the study of supported lipid
bilayers, allowing the topography of membrane components to be
acquired with molecular resolution under physiological condi-
tions [33]. Also, there are several recent papers which deal withOHO
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Fig. 1. Chemical structure of the examined compounds: (2R)-N-(adamant-1-yl)-3-(α,β-D-man
methylpropanoyl]-D,L-(adamant-2-yl)glycyl-L-alanyl-D-isoglutamine (b).the application of AFM for the characterization of nanoscale drug
delivery systems [34–36].
In the present work we were primarily interested to study wheth-
er the adamantyl moiety, due to its lipophilic properties, can pene-
trate into the lipid core of the bilayer. In such a case it might be
possible that the hydrophilic part with the mannose would be ex-
posed on the liposome surface. To observe the expected behavior of
the tested compounds, ConA, a lectin, which speciﬁcally binds α-D-
mannosyl and α-D-glucosyl residues, was used. In consequence, if
the mannose were exposed on the liposome surface, ConA would tie
the liposomes together. As a result the increase in vesicle size, the
changes of shape and surface and aggregation of liposomes would
be observed.
2. Materials and methods
L-α-Phosphatidylcholine, type XI-E: from fresh egg yolk (egg-PC),
cholesterol from porcine liver (CHL), and dicetylphosphate (DCPh)
were from Sigma-Aldrich (St. Louis, MO, USA). [(2R)-N-(adamant-1-
yl)-3-(α,β-D-mannopyranosyloxy)-2-methylpropanamide and (2R)-N-
[3-(α-D-mannopyranosyloxy)-2-methylpropanoyl]-D,L-(adamant-
2-yl)glycyl-L-alanyl-D-isoglutamine] were prepared by a previously
described procedure [29,30]. Acetonitrile and triﬂuoroacetic acid (TFA)
were of HPLC grade from Merck (Darmstadt, Germany). A daily supply
of water was obtained from Millipore Simplicity-Personal ultra pure
water system (Bedford, MA, USA). Most of the chemical reagents used
in the syntheses were obtained from Sigma-Aldrich (St. Louis, MO, USA)
Chemicals for buffers and solutions were from Kemika (Zagreb, Croatia),
unless stated otherwise.
Chromatographic analyses were carried out using the Waters HPLC
System equipped with 2996 PDA detector and Empower software
(Milford, MA, USA). A LiChrosorb RP-18 column, 244×4 mm, 5 μm,
and a LiChrospher guard column 100 RP-18 (5 μm) were used (Merck,
Darmstadt, Germany). Analyses were run at a ﬂow rate of 1.0 mL/min
at room temperature and the eluate wasmonitored at 200 nm. The gra-
dient solvent system used was made of acetonitrile containing 0.035%
TFA and water containing 0.05% TFA. The percentage of acetonitrile at
0, 20 and 25 min was 10, 60 and 90, respectively and a running time
was 25 min. The percentage of each peak in the respective chromato-
gramswas calculated by the integration of the UV response (peak area).
2.1. Preparation of liposomes
Multilamellar, negatively charged liposomes were prepared by
hydration of thin lipid ﬁlms following previously described methods
[20]. Brieﬂy, egg-phosphatidylcholine, cholesterol and dicetylpho-
sphate (total mass of lipid was 10 mg, giving a molar ratio of 7:5:1)
were dissolved in 2 mL chloroform:ethanol (1:1). 1 mL of the meth-
anol solution (10 mM) of mannosylated 1-aminoadamantane or
mannosylated adamantyltripeptides was added to the lipids in the
chloroform:ethanol solution. After rotary evaporation of the solvent
the remaining lipid ﬁlm was dried in vacuum for an hour and thenO
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nopyranosyloxy)-2-methylpropanamide (a) and (2R)-N-[3-(α-D-mannopyranosyloxy)-2-
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tion 10 mM and pH 7.4. The liposome suspension was left overnight
at 4 °C to swell and stabilize. Liposomes were separated from non-
encapsulated material by centrifugation. The liposome pellets
obtained after centrifugation were resuspended in 1 mL HEPES buff-
er and liposome size was reduced by repeated extrusion through the
200 nm polycarbonate membranes using the 0.5 mL extruder (Lipo-
soFast, Avestin Inc., Canada).2.2. Ultracentrifugation
In order to separate nonencapsulated material from liposomes and
to determine the encapsulation efﬁciency of mannosylated 1-
aminoadamantane andmannosylated adamantyltripeptides ultracen-
trifugation was used. The liposome suspensions (1 mL) were mixed
with 2.5 mL HEPES buffer and placed into polycarbonate centrifuga-
tion tubes and centrifuged in the ultracentrifuge (Beckman model
L5-65, Beckman Coulter TM, USA) for 1 h at 300,000×g. After centri-
fugation the supernatants were separated from the pellets and sub-
mitted to HPLC analysis. The pellets were resuspended in 1 mL
HEPES buffer and used for further investigations.2.3. Determination of the entrapment efﬁciency
The entrapment efﬁciency of mannosylated 1-aminoadamantane
and adamantyltripeptides was determined by HPLC in the superna-
tants following ultracentrifugation. HPLC measurements were done
on aWaters 600 HPLC System, equipped with PDA detector, utilizing
an analytical LiChrosorb RP-18 column (244×4 mm, 5 μm, Merck,
Darmstadt, Germany) containing a Merck guard column LiChro-
spher 100 RP-18 under gradient conditions. All analyses were per-
formed at a ﬂow rate of 1.0 mL/min at room temperature. The
eluate was monitored at 200 nm. The standard curves of examined
compounds were constructed for each compound prior to the ana-
lyses of the supernatants from the liposome preparations. The con-
centrations of 0.0625; 0.125; 0.25; 0.5 and 1 mg/mL were used for
standard curves. Samples of 20 μL of supernatants were injected onto
the column using the autosampler. The amount of the entrapped solute
was then calculated by subtracting the obtained value from the total
amount of the particular compound used for liposome preparation
and entrapment efﬁciency expressed as the percentage of the starting
amount.2.4. Dynamic light scattering measurement (DLS)
The size distribution and zeta potential of the liposomes were
measured using Zetasizer Nano ZS (Malvern, UK) equipped with
green laser (532 nm). Intensity of scattered light was detected at
the angle of 173°. All measurements were conducted at 25 °C. All
data processing was done by the Zetasizer software 6.20 (Malvern
instruments). 125 μL of liposome suspension was added to 1.5 mL
10 mM borate buffer, pH 7.5, containing 1 mM CaCl2 and 1 mM
MnCl2. The size of liposomes is expressed as average diameter (z-
average) that is obtained from the Zetasizer Nano software, which
calculates it from the signal intensity. Each sample was measured
ten times and the results were expressed as the average value. The
presence of accessible mannose on the surface of the liposomes
was determined by measuring an increase in the mean particle size
of liposome suspensions after the addition of concanavalin A
(ConA). 300 μL of ConA with concentration of 1 mg/mL in the same
borate buffer was added to the liposome suspensions and the parti-
cle size was measured continuously for further 2 h at room
temperature.2.5. Molecular modeling — molecular dynamics simulation, computa-
tional detail
Starting structures (2R)-N-(adamant-1-yl)-3-(α-D-mannopyrano-
syloxy)-2-methylpropanamide and (2R)-N-[3-(α-D-mannopyranosy-
loxy)-2-methylpropanoyl]-D-(adamant-2-yl)glycyl-L-alanyl-D-isogluta-
mine were created with the Sybyl molecular modeling package [37].
Prior to performing conformational searches on the databases, the
both structures were ﬁrst minimized employing a TRIPOS Force Field
and Gasteiger–Hückel charges using the conjugate gradient method
until gradient of 0.05 kcal/(mol Å). Molecular dynamics (MD) simula-
tions using NTV ensemble were performed in vacuo at constant tem-
perature (300 K) using 8 Å cut-off for non-bonded interactions. The
lower energy conformations generated by the MD run were further
subjected to simulated annealing (SA). The calculation was carried
out in vacuo by SYBYL's simulated annealing module [37]. Hence, se-
lected low-energy conformers of molecules a and b (Fig. 1) were sub-
jected to MD-SA, no restrictions were applied during annealing to
determine the lowest energy structures of molecules. The annealing
process involved heating the system to 700 K for 500 fs and gradually
annealing it to 200 K for 1000 fs, for total of 10 cycles. This insured
that several different low energy conformations of each molecule
were obtained. These were further minimized employing the same
minimization technique described above. This eventually helped to ob-
tain lowest energy conformer in each of the structure databases. The
electrostatic isopotential surfaces were calculated for low energy struc-
ture conformers of a and b. Isosurface of electron density has been
colorized to show the electrostatic potential value at each point on
the electronic density isosurface (isovalue=0.002 electrons/a.u.3)
[38]. Intensity of the surface color indicates a different electrostatic po-
tential to show the hydrophobic and hydrophilic regions of the mole-
cule [39].
2.6. Atomic force microscopy measurement (AFM)
AFM imaging was performed using a Multimode AFM with
Nanoscope IIIa controller (Bruker, Billerica USA) with a vertical en-
gagement (JV) 125 μm scanner. The tapping mode was applied
using silicon tip (TESP, Bruker, nom. freq. 320 kHz, nom. spring
constant of 42 N/m) and with scan resolution of 512 samples per
line. A 5 μL of each liposome suspension (0.5 mg lipids/mL borate
buffer) was pipetted directly onto freshly cleaved hydrophilic sur-
face of mica. After 40 min of the deposition, samples were rinsed
with ultrapure water and dried under the gentle stream of nitro-
gen. To minimize the forces of interaction between the tip and
the surface during the imaging, the ratio of the set point amplitude
to the free amplitude (A/A0) was maintained at 0.8–0.9 (soft tap-
ping). Measurements were performed in air at room temperature
and 50–60% relative humidity. Processing of images and analysis
was carried out using NanoScope™ software (Digital Instruments,
version V614r1). All images are presented as raw data except for
the ﬁrst-order two-dimensional ﬂattening.
2.7. Statistics
Statistical analyses were performed using Statistica 6.0 for Win-
dows, StatSoft Inc. The signiﬁcant difference between experimental
groups was evaluated by Kruskal–Wallis ANOVA, followed by multi-
ple Mann–Whitney U-nonparametric tests. A probability value less
than 0.05 (pb0.05) was considered signiﬁcant.
3. Results
The data obtained from liposome preparation testings, i.e. the entrap-
ment efﬁciency, size, shape and surface changes, DLS and AFM, all indi-
cated that encapsulation of the mannosylated adamantyl compounds
Table 1
Zeta potential, size of liposome formulations expressed as z-average measured by DLS
and polydispersity index (PdI). The results are expressed as an average value±stan-
dard deviation (SD) of three separate experiments. Each experiment has at least 10
measurements.
Liposome preparations Zeta potential/
mV
z-Average/
nm⁎⁎
PdI
Empty liposomes −56.0±1.6 166±32a 0.38±0.03
Liposomes with
mannosylated
1-aminoadamantane
−54.6±1.5 182±28a 0.25±0.01
Liposomes with
mannosylated
adamantyltripeptides
−52.6±0.46 224±3b 0.46±0.03
Empty liposomes+ConA N/A 176±22a 0.54±0.08
Liposomes with
mannosylated
1-aminoadamantane+ConA
N/A 256±18c 0.67±0.07
Liposomes with
mannosylated
adamantyltripeptides+ConA
N/A 267±11c 0.84±0.03
N/A: not applicable.
⁎⁎, a, b, c denote pb0.05, mean values marked with the same letter are not signiﬁcantly
different.
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Fig. 2. The size distribution by intensity of empty liposomes (a), liposomes with man-
nosylated 1-aminoadamantane (b) and liposomes with mannosylated adamantyltri-
peptides (c) after ConA was added in liposome suspensions.
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curves constructed for the entrapment efﬁciency determination exhib-
ited an excellent linear regression value (R2=0.99). The retention
times of encapsulated compounds under given gradient conditions
were; mannosylated 1-aminoadamantane has a retention time of
16.64 min, and diastereoisomers of mannosylated adamantyltripep-
tides, (α-D-Man-(R)-OCH2CH(CH3)CO-L-(adamant-2-yl)Gly-L-Ala-
D-isoGln) and (α-D-Man-(R)-OCH2CH(CH3)CO-D-(adamant-2-yl)
Gly-L-Ala-D-isoGln) have retention times of 12.84 min and
16.25 min, respectively. The amount (mg) of the entrapped material
is expressed as a percentage of the amount of the experimental
substance used for incorporation. It was shown that 29.4% of mannosy-
lated 1-aminoadamantane was entrapped into liposomes in compari-
son to 21.2% of the entrapped mannosylated adamantyltripeptides.
The results obtained by DLS for empty liposomes and liposomes
with mannosylated 1-aminoadamantane and mannosylated ada-
mantyltripeptides before and after the interaction with ConA are
presented in Table 1. Size of the liposomes is given as z-average di-
ameter, a parameter which is most commonly used for expressing
the size of the liposomes [40,41]. As an estimate of the width of
size distributions values of the polydispersity index (PdI) are given
[42]. The increase of the liposome size when the compounds were
encapsulated in comparison with empty liposomes was observed.
This increase is statistically signiﬁcant for the liposomes with man-
nosylated adamantyltripeptides.
In order to be able to assess the presence of mannose residues on
the surface of liposomes, ConA was added to the liposome disper-
sions. Addition of ConA resulted in further increase of z-average
values, which was statistically signiﬁcant in the case of the liposomes
with encapsulated compounds. Size distribution by intensity (Fig. 2)
revealed that in the case of liposome formulations with encapsulated
mannosylated conjugates after addition of ConA larger aggregates
were formed (up to 10%). Their sizes were 4816±324 nm in the
case of the liposomes with mannosylated 1-aminoadamantane and
3846±1105 nm in the case of the liposomes with mannosylated ada-
mantyltripeptides, respectively. Incorporation of mannosylated 1-
aminoadamantane or mannosylated adamantyltripeptides inﬂuenced
slightly the distribution of ions in electrical double layer resulting in
somewhat lower zeta potential of mannosylated liposomes compared
to that of empty liposomes.
In Fig. 3 the electrostatic potential surfaces of the examined com-
pounds are presented. Because electrostatic potential correlates with
the dipole moment, electronegativity and partial charges, it provides
a visual method for elucidating the relative polarity of the examinedmolecules. Low energy structure conformers presented in Fig. 3 clear-
ly demonstrate the signiﬁcant difference in molecular geometry of
compounds a and b, regarding the hydrophilic part of the molecule,
as well as the ratio of the hydrophilic and hydrophobic surfaces. The
relative lipophilicity for both compounds was estimated by calcula-
tion of average logP values using the public domain software
ALOGPS 2.1. [43]. The average logP was 0.38 for mannosylated 1-
aminoadamantane and 1.10 for mannosylated adamantyltripeptide,
respectively.
AFM experiments were performed on lipid layers formed by depo-
sition of liposome suspension on mica surface. Typical AFM images
are shown in Fig. 4. Liposomes were transformed into ﬂat island
structure due to spreading and rapture of individual liposomes
when deposited on mica surface [44]. AFM analysis of the islands
formed by empty liposomes is shown in Fig. 4a. The average height
of ﬂat circular bilayer domains was 4.8 nm. Liposomes with mannosy-
lated 1-aminoadamantane (Fig. 4b) formed also ﬂat circular lipid do-
mains with the average height of 5.3 nm. In contrast, the incorporated
mannosylated adamantyltripeptide molecules grouped into small do-
mains that rise 1.3 nm above the bilayer surface (Fig. 4c). The shape
of lipid domains is not circular. The shape of bilayer patches on the
solid support provides the ﬁrst information about their collective lat-
eral mobility [45]. Laterally mobile patches tend to reshape into
Fig. 3. Electrostatic potential plotted on the electron density surface (isovalue=0.002 electrons/a.u.3) of the modeled structure of mannosylated 1-aminoadamantane (a) and man-
nosylated adamantyltripeptide (b) molecules in the same orientation. Contour levels: hydrophilic regions are red (negative potential) and blue (positive potential) while hydro-
phobic regions are green.
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bility resume noncircular shape. Using the above mentioned criterion,
we assume that incorporated mannosylated 1-aminoadamantane
molecules are evenly distributed in the lipid layer and therefore do
not impose restrictions to liposome collective mobility.
4. Discussion
Liposomes are versatile membrane mimetic system and molecular
recognition between liposomes can be used in modeling recognition
occurring between cells [45,46]. Among other applications the use
of liposomes in immunology has demonstrated that they may have
considerable practical utility as carriers of antigens and adjuvants
[47–49]. Our previous investigations have been directed toward the
synthesis of a new class of immunomodulators and their encapsula-
tion into liposomes. The interaction of examined immunostimulators
and a lipid bilayer in liposomes was conﬁrmed by EPR spectroscopy
[21]. The understanding of how these compounds interact with the
lipid bilayer is of great interest. Several studies reported so far, were
concerned with the interaction of 1-aminoadamantane with the
lipid membrane. Various methods were used for this purpose
[50,51]. X-ray diffraction method was used to study the amantadine
position in the lipid bilayer and the results revealed two sites of
amantadine location within the bilayer, one site close to the bilayer
surface and the other much deeper [50]. The EPR spectroscopy
study of 1-aminoadamantane has also been reported [51]. The spin-
labeled 1-aminoadamantane was synthesized and the results
revealed that although the new molecule was more hydrophilic
than the unlabelled 1-aminoadamantane, it could nevertheless pene-
trate into the lipid core of the bilayer and interact with the lipids.
Liquid-state NMR and molecular-dynamics simulations were used to
study the distribution and localization of amantadine in the phospho-
lipid membrane [52,53].
The interaction of the liposomebilayerwith adamantylglycopeptides
has not been reported so far, although the biological activities of lipo-
some formulation of structural related compounds, such as desmuramyl
compounds, adamantylamide-L-alanyl-D-isoglutamine, were described
[54]. Furthermore, adamantoylated monosaccharides were recognized
as suitable compounds for modiﬁcation of the properties of
cyclodextrin-containing materials for biological applications [55]. Theshape of the adamantylmoietyﬁts precisely into theβ-cyclodextrin cav-
ity. Also, carbohydrate decorated drug delivery systems have become an
increasingly popular topic in recent years not only for targeted drug de-
livery but also in supramolecular chemistry. Host–guest interaction and
dynamicmultivalentmolecular recognition have been studied by sever-
al groups [56–58].
We now report the encapsulation of the mannosylated 1-
aminoadamantane and mannosylated adamantyltripeptides into li-
posomes and the effects of encapsulated compounds on the structure
of liposome bilayers. The obtained data conﬁrmed that the adamantyl
moiety, due to its lipophilic properties, is located within the lipid bi-
layer while the hydrophilic part with the mannose is exposed on
the liposome surface.
The RP-HPLC method used for the entrapment efﬁciency determi-
nation of the mannosylated 1-aminoadamantane and mannosylated
adamantyltripeptides, followed the previously described method
[20] for analyses of peptidoglycans and adamantyltripeptides with
small changes in gradient compositions. The results are in accordance
with our previously obtained results. Several factors affect encapsula-
tion of drugs in liposomes such as liposome size and type, charge on
the liposome surface, method of preparation, ionic strength of the
buffer used and chemical properties of the drug to be encapsulated
[59]. The lower value for the entrapment efﬁciency of mannosylated
adamantyltripeptides in comparison to that of mannosylated 1-
aminoadamantane could be explained as being a result of the differ-
ence in size and lipophilicity of the examined molecules. Molecular
modeling (Fig. 3) showed that the conformers with the lowest energy
of mannosylated 1-aminoadamantane and mannosylated adamantyl-
tripeptides are 8.8 and 17.5 long, respectively.
It has to be stressed that the multilamellar, (despite the extrusion
of liposome suspensions through the 200 nm size polycarbonate
membrane) negatively charged liposomes were prepared and the
modiﬁed ﬁlm method was used for the examined compound encap-
sulation. The choice of lipid composition of liposome bilayers and
method of liposome preparations was based on our previous investi-
gations [20].
For evaluation of the encapsulation of examined compounds into li-
posomes DLS and AFMwere used. DLS is an established technique used
to measure hydrodynamic sizes, polydispersities and aggregation ef-
fects of different samples. It has also been used in the nanotechnology
Fig. 4. AFM images showing lipid patches after deposition of liposome suspensions on mica surface. (a) Empty liposomes; (b) Liposomes with mannosylated 1-
aminoadamantane; (c) Liposomes with mannosylated adamantyltripeptides. Images are presented as height data with a vertical proﬁle along indicating lines. Scan size
1 μm×1 μm, vertical scale 15 nm.
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made of different materials [60]. The obtained results conﬁrmed the in-
crease of liposome size after encapsulation of examined compounds, in
liposome solutions the same as on the molecular level.
To conﬁrm the presence of mannose on the surface of liposomes
the aforementioned lectin, ConA, was used. Because most lectins pos-
sess multiple carbohydrate-binding sites, the interaction of lectins
with the carbohydrate decorated vesicles might result in aggregation
of the vesicles, and such effect can be easily detected as an increase in
optical density of the vesicle solution (agglutination assay). Many
studies have focused on design and synthesis of different nanoparti-
cles that display a large number of carbohydrates at their surface
and thus mimic the glycocalyx of cells [56,57]. The particular lectin
requires a characteristic critical concentration of complementarycarbohydrates at the vesicle surface. The results obtained by DLS in-
vestigations have revealed that, after addition of ConA to the lipo-
some suspension, the increase of z-average was observed. As shown
by the distribution by intensity, the population of larger aggregates
of liposomes appeared (Fig. 2). It was ascribed to the speciﬁc binding
of the ConA to the mannose present on the surface and agglutination
of the prepared liposomes as schematically shown in Fig. 5. The ag-
glutination was not observed after ConA was added to the prepara-
tion of empty liposomes. Moreover the increase in size of the empty
liposomes after addition of ConA was not statistically signiﬁcant, indi-
cating nonsigniﬁcant interaction of ConA with liposomes without
mannose moiety exposed at the surface.
AFM studies of liposome bilayers revealed the difference in the in-
corporation proﬁle of the examined mannosylated compounds. While
Mannosylated  
adamantyltripeptides 
Con A 
Fig. 5. Schematic presentation of ConA interaction with mannosylated adamantyltri-
peptides anchored via the adamantyl moiety in the lipid bilayer; it does not imply
any stoichiometry of the ConA–liposome complex.
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distributed in a lipid bilayer, the larger and more hydrophilic manno-
sylated adamantyltripeptide molecules grouped into small domains
that rise 1.3 nm above the bilayer surface. The modeled structures
(Fig. 3) represent realistic models from energetic and geometrical
point of view and offer possible explanation of the difference in
their incorporation proﬁle. The molecule size and molecular geome-
try as well as the different ratios of hydrophilic and hydrophobic sur-
faces in the presented structures are the factors that are responsible
for arrangement of particular molecule in the lipid bilayer. The values
of relative lipophilicity, are also important and suggest the differences
in interactions with lipid bilayer. Obviously the smaller mannosylated
1-aminoadamantane molecule is more lipophilic (logP is 0.38) and
presumably has a higher afﬁnity to the lipids in bilayers. On the con-
trary, the mannosylated adamantyltripeptides are more hydrophilic
(logP is 1.10) and might cause the association into domains within
the lipid bilayer.
Similar results were previously published. Fluorescently labeled
glycolipid whose mannosamine head group was speciﬁcally recog-
nized by concanavalin A has been studied. Atomic force microscopy
revealed that the binding of ConA to the mannosamine causes the
glycolipid reorganization in the membrane [61]. They found that the
glycolipid formed 10 nm wide dendrite structures throughout the
membrane and the bound ConA was associated with those nanoscale
features. This is signiﬁcant in terms of understanding the triggering of
the cell signaling cascade that results in the cellular activation which
has been achieved through the speciﬁc interaction of proteins with
membrane receptors.
In conclusion, the liposomal preparations of newly synthesized
mannosylated 1-aminoadamantane and mannosylated adamantyltri-
peptides were characterized in order to determine the entrapment ef-
ﬁciency of examined compounds, vesicle size and morphology.
Concanavalin A allowed us to evaluate the speciﬁc exposure of the
mannosyl head group on the liposome surface. After the ConA was
added to the liposome suspensions, the increase in liposome size,
expressed as z-average and appearance of aggregates, was observed.
The enlargement of liposomes was ascribed to the speciﬁc bindingof the ConA to the mannose present on the surface of the prepared li-
posomes. The AFM analysis provided topographical information on
three classes of liposomes at the nanometer level and conﬁrmed the
incorporation of the adamantyl moiety in the lipid bilayer of lipo-
somes. Further investigations in order to better understand and de-
scribe the observed phenomena are required. Based on these
studies, the adamantyl moiety may be considered as a potential
membrane anchor for different carbohydrate molecules or other mol-
ecules of interest which could be bound on it and thus exposed on li-
posome surfaces and as such used in targeted drug delivery. Also, this
approach might be a useful model for investigation of speciﬁc protein
interactions with membrane receptors.Acknowledgements
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